CR11307A - Vacunas - Google Patents
VacunasInfo
- Publication number
- CR11307A CR11307A CR11307A CR11307A CR11307A CR 11307 A CR11307 A CR 11307A CR 11307 A CR11307 A CR 11307A CR 11307 A CR11307 A CR 11307A CR 11307 A CR11307 A CR 11307A
- Authority
- CR
- Costa Rica
- Prior art keywords
- malaria
- vaccines
- preeritrocyte
- circumesporozoite
- medicament
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 201000004792 malaria Diseases 0.000 abstract 2
- 241000223960 Plasmodium falciparum Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La invencion se refiere al uso de un antigeno derivado de la proteina circumesporozoito (CS) de Plasmodium falciparum que se expresa en la etapa preeritrocita de la infeccion por malaria combinado con un adyuvante farmaceuticamente aceptable, en la fabricacion de un medicamento para vacunar bebes contra la malaria.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95544507P | 2007-08-13 | 2007-08-13 | |
US95733807P | 2007-08-22 | 2007-08-22 | |
US98280107P | 2007-10-26 | 2007-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR11307A true CR11307A (es) | 2010-05-24 |
Family
ID=39870250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR11307A CR11307A (es) | 2007-08-13 | 2010-03-10 | Vacunas |
Country Status (21)
Country | Link |
---|---|
US (1) | US9066899B2 (es) |
EP (1) | EP2190470B1 (es) |
JP (1) | JP5508266B2 (es) |
KR (1) | KR20100068390A (es) |
AP (1) | AP2010005166A0 (es) |
AR (1) | AR067905A1 (es) |
AU (1) | AU2008288508B2 (es) |
BR (1) | BRPI0815199A2 (es) |
CA (1) | CA2695477A1 (es) |
CL (1) | CL2008002361A1 (es) |
CR (1) | CR11307A (es) |
DO (1) | DOP2010000056A (es) |
ES (1) | ES2658347T3 (es) |
MA (1) | MA31693B1 (es) |
MX (1) | MX2010001752A (es) |
NZ (1) | NZ583150A (es) |
TR (1) | TR201802221T4 (es) |
TW (1) | TW200924791A (es) |
UY (1) | UY31285A1 (es) |
WO (1) | WO2009021931A1 (es) |
ZA (1) | ZA201001029B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY31285A1 (es) | 2007-08-13 | 2009-03-31 | Vacunas | |
MX2011011676A (es) | 2009-05-05 | 2012-04-02 | Cadila Healthcare Ltd | Vacuna combinada sarampion-paludismo. |
US8889146B2 (en) | 2009-06-24 | 2014-11-18 | Glaxosmithkline Biologicals, Sa | Vaccine |
AU2010315868B2 (en) * | 2009-11-05 | 2012-12-20 | The United States Of America As Represented By The Secretary Of The Navy | Plasmodium falciparum sporozoite and liver stage antigens |
EP2385107B1 (en) * | 2010-05-03 | 2016-08-24 | Institut Pasteur | Lentiviral vector based immunological compounds against malaria |
BR112013007051A2 (pt) | 2010-09-27 | 2019-07-02 | Inovio Pharmaceuticals Inc [Us/Is] | construções de antígenio de consenso e vacinas feitas dos mesmos e métodos de uso das mesmas para tratar a malária |
US20120244178A1 (en) * | 2011-03-25 | 2012-09-27 | Denise Doolan | Plasmodium falciparum antigens |
CN102268093B (zh) * | 2011-06-27 | 2013-06-26 | 广东药学院 | 一种肝靶向肽与人干扰素a2b融合蛋白及其制备方法和应用 |
US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
GB201416773D0 (en) * | 2014-09-23 | 2014-11-05 | Glaxosmithkline Biolog S A And Chancellor Masters And Scolars Of The The University Of Oxford | Novel Methods For Including An Imune Response |
WO2016184784A1 (en) | 2015-05-15 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1 |
JP2022526334A (ja) | 2019-03-25 | 2022-05-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 新たなタウ種を標的化することによるタウオパチー障害の処置の方法 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
EP0071705B1 (en) | 1981-05-21 | 1989-11-23 | The Wellcome Foundation Limited | Protozoal antigen |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
GB9002512D0 (en) | 1990-02-05 | 1990-04-04 | 3I Res Expl Ltd | Polypeptides and dna encoding same |
GB9012580D0 (en) | 1990-06-06 | 1990-07-25 | Univ Nijmegen | Novel protein |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5198535A (en) | 1991-01-10 | 1993-03-30 | The United States Of America As Represented By The Secretary Of The Navy | Protective malaria sporozoite surface protein immunogen and gene |
DE69228698T2 (de) | 1991-11-16 | 1999-09-16 | Smithkline Beecham Biologicals S.A., Rixensart | HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG |
ZA929870B (en) | 1991-12-23 | 1993-08-18 | Duphar Int Res | Adjuvants |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
ATE204762T1 (de) | 1993-03-23 | 2001-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
ATE420171T1 (de) | 1994-07-15 | 2009-01-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
GB9616351D0 (en) | 1996-08-02 | 1996-09-11 | Smithkline Beecham Biolog | Vaccine composition |
US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
EP0930893B1 (en) | 1996-10-11 | 2005-04-13 | The Regents of The University of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
AU6524698A (en) | 1997-03-29 | 1998-10-22 | Ji Hoon Park | Continuous injecting apparatus |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
EP2050465B1 (en) | 1997-08-29 | 2014-06-11 | Antigenics Inc. | Compositions comprising the adjuvant QS-21 and polysorbate or cyclodextrin as excipient |
DE69815692T2 (de) | 1997-09-05 | 2004-04-29 | Glaxosmithkline Biologicals S.A. | Öl in wasser emulsionen mit saponinen |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
EP1423405A4 (en) | 2001-03-26 | 2005-01-05 | Us Army | AMA-1 PROTEIN OF PLASMODIUM FALCIPARUM AND ITS APPLICATIONS |
AU2002360429A1 (en) | 2001-11-26 | 2003-06-10 | Avigen, Inc. | Methods for producing stocks of recombinant aav virions |
PL376792A1 (pl) | 2002-10-23 | 2006-01-09 | Glaxosmithkline Biologicals S.A. | Sposoby szczepienia przeciwko malarii |
US7550275B2 (en) | 2002-11-12 | 2009-06-23 | The United States Of America As Represented By The Secretary Of The Navy | Expression, purification and uses of a Plasmodium falciparum liver stage antigen 1 polypeptide |
GB0420634D0 (en) * | 2004-09-16 | 2004-10-20 | Glaxosmithkline Biolog Sa | Vaccines |
KR20070104881A (ko) | 2004-10-14 | 2007-10-29 | 크루셀 홀란드 비.브이. | 말라리아 프라임/부스트 백신 |
GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
EP1754717A1 (en) | 2005-08-19 | 2007-02-21 | Université de Lausanne | Antigenic peptides and their use |
UY31285A1 (es) | 2007-08-13 | 2009-03-31 | Vacunas | |
US9821046B2 (en) * | 2013-01-21 | 2017-11-21 | Oxford University Innovation Limited | Composition and uses thereof |
-
2008
- 2008-08-11 UY UY31285A patent/UY31285A1/es unknown
- 2008-08-11 KR KR1020107005518A patent/KR20100068390A/ko active IP Right Grant
- 2008-08-11 EP EP08787080.4A patent/EP2190470B1/en active Active
- 2008-08-11 CA CA2695477A patent/CA2695477A1/en active Pending
- 2008-08-11 TW TW097130604A patent/TW200924791A/zh unknown
- 2008-08-11 AU AU2008288508A patent/AU2008288508B2/en not_active Ceased
- 2008-08-11 NZ NZ583150A patent/NZ583150A/en not_active IP Right Cessation
- 2008-08-11 AR ARP080103497A patent/AR067905A1/es not_active Application Discontinuation
- 2008-08-11 CL CL2008002361A patent/CL2008002361A1/es unknown
- 2008-08-11 ES ES08787080.4T patent/ES2658347T3/es active Active
- 2008-08-11 AP AP2010005166A patent/AP2010005166A0/en unknown
- 2008-08-11 WO PCT/EP2008/060505 patent/WO2009021931A1/en active Application Filing
- 2008-08-11 US US12/673,272 patent/US9066899B2/en active Active
- 2008-08-11 BR BRPI0815199 patent/BRPI0815199A2/pt not_active Application Discontinuation
- 2008-08-11 TR TR2018/02221T patent/TR201802221T4/tr unknown
- 2008-08-11 MX MX2010001752A patent/MX2010001752A/es active IP Right Grant
- 2008-08-11 JP JP2010520550A patent/JP5508266B2/ja active Active
-
2010
- 2010-02-11 ZA ZA2010/01029A patent/ZA201001029B/en unknown
- 2010-02-11 DO DO2010000056A patent/DOP2010000056A/es unknown
- 2010-03-08 MA MA32675A patent/MA31693B1/fr unknown
- 2010-03-10 CR CR11307A patent/CR11307A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP5508266B2 (ja) | 2014-05-28 |
EP2190470A1 (en) | 2010-06-02 |
US20110212159A1 (en) | 2011-09-01 |
TW200924791A (en) | 2009-06-16 |
CA2695477A1 (en) | 2009-02-19 |
US9066899B2 (en) | 2015-06-30 |
WO2009021931A1 (en) | 2009-02-19 |
AU2008288508B2 (en) | 2014-05-01 |
AU2008288508A1 (en) | 2009-02-19 |
KR20100068390A (ko) | 2010-06-23 |
BRPI0815199A2 (pt) | 2015-03-31 |
JP2010535836A (ja) | 2010-11-25 |
AP2010005166A0 (en) | 2010-02-28 |
ZA201001029B (en) | 2011-04-28 |
DOP2010000056A (es) | 2010-07-31 |
EP2190470B1 (en) | 2017-12-13 |
TR201802221T4 (tr) | 2018-03-21 |
ES2658347T3 (es) | 2018-03-09 |
CL2008002361A1 (es) | 2009-08-07 |
MA31693B1 (fr) | 2010-09-01 |
CN101820901A (zh) | 2010-09-01 |
MX2010001752A (es) | 2010-03-10 |
NZ583150A (en) | 2012-05-25 |
UY31285A1 (es) | 2009-03-31 |
AR067905A1 (es) | 2009-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR11307A (es) | Vacunas | |
UA93508C2 (en) | Anti-malaria vaccine | |
EA201291105A1 (ru) | Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора | |
BRPI0515334A (pt) | uso de um antìgeno de plasmodium | |
EA200970013A1 (ru) | Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы | |
CR10555A (es) | Vacunas para malaria | |
EA200701595A1 (ru) | Устойчивые к спиртам лекарственные формы | |
DE122011100054I1 (de) | Influenza vakzinzusammensetzungen zur intradermaler verabreichung. | |
CL2014002415A1 (es) | Composición inmunogénica que permite aumentar una respuesta inmunitaria a un patógeno, particularmente viral, que comprende una glicoproteína antigénica del patógeno, donde la glicoproteina está parcialmente glicosilada en al menos un sitio de glicosilación; y vacuna útil para inmunizar un mamífero (div. sol. n° 2354-11). | |
AR060130A1 (es) | Formulacion de un anticuerpo monoclonal humano anti- igf-1r | |
MA29406B1 (fr) | Vaccin toxoide alpha de c. perfringens | |
CR10559A (es) | Vacuna de influenza | |
UY33297A (es) | Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas | |
WO2008054535A3 (en) | Novel influenza m2 vaccines | |
BR112012016048A2 (pt) | "exossomas derivados de reticulócitos infectados com plasmodium sp., método para obter os mesmos e usos dos mesmos". | |
CY1112575T1 (el) | Βελτιωμενα αδρανοποιημενα εμβολια fcv | |
BRPI0606614A2 (pt) | peptìdeos para distribuição de vacinas na mucosa | |
MX2007002659A (es) | Composicion vacunal contra el virus de la hepatitis c. | |
EA201200538A1 (ru) | Арабиногалактан для повышения приобретенного иммунного ответа | |
UY31510A1 (es) | Vacunacontra la malaria, especifica para el parasito plasmodium falciparum | |
UY31574A1 (es) | Vacunas contra la malaria | |
BRPI0414073A (pt) | método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo | |
NZ580603A (en) | Intradermal influenza vaccine | |
WO2010064208A3 (en) | Msp2 antigenic peptides and their use | |
WO2010023452A3 (en) | Nematode vaccine |